Antev: Phase 3 ready, Teverelix, a long acting injectable peptide GnRH antagonist. Lead indication for prostate cancer, followed by benign prostatic hyperplasia (BPH), acute urinary retention (AUR), uterine fibroids and endometriosis. Over 450 subjects have been dosed over 850 times to date with no serious adverse reactions and good local tolerance.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Marketed, Phase III, Phase l or ll, Pre-Clinical Stage
Disease Space
Men's Health, Oncology, Women's Health
Industry
Biotechnology
Listing
Private
Website:
Address:
2nd Floor
106 New Bond Street
London, W1S 1DN
United Kingdom